SK283711B6 - Liečivo na liečenie úzkosti a panického strachu - Google Patents

Liečivo na liečenie úzkosti a panického strachu Download PDF

Info

Publication number: SK283711B6
Authority: SK; Slovakia
Prior art keywords: gabapentin; test; anxiety; effects; treatment
Prior art date: 1994-07-27

Application number

SK90-97A

Other languages

English (en)

Slovak (sk)

Other versions

SK9097A3 (en

Inventor

Geoffrey Neil Woodruff

Nicolas Steven Gee

Lakhbir Singh

Jason Peter Brown

Original Assignee

Warner-Lambert Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-07-27

Filing date

1995-07-11

Publication date

2003-12-02

1995-06-06 Priority claimed from US08/445,398 external-priority patent/US5792796A/en

1995-07-11 Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company

1998-05-06 Publication of SK9097A3 publication Critical patent/SK9097A3/sk

2003-12-02 Publication of SK283711B6 publication Critical patent/SK283711B6/sk

Links

208000019901 Anxiety disease Diseases 0.000 title claims abstract description 19
230000036506 anxiety Effects 0.000 title claims abstract description 19
239000003814 drug Substances 0.000 title claims abstract description 13
150000003839 salts Chemical class 0.000 claims abstract description 12
125000000217 alkyl group Chemical group 0.000 claims abstract description 5
241000124008 Mammalia Species 0.000 claims abstract description 4
238000004519 manufacturing process Methods 0.000 claims abstract description 3
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 128
229960002870 gabapentin Drugs 0.000 claims description 61
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims description 2
229910052739 hydrogen Inorganic materials 0.000 claims description 2
239000001257 hydrogen Substances 0.000 claims description 2
230000002265 prevention Effects 0.000 abstract description 3
206010033664 Panic attack Diseases 0.000 abstract description 2
208000019906 panic disease Diseases 0.000 abstract description 2
238000012360 testing method Methods 0.000 description 40
150000001875 compounds Chemical class 0.000 description 25
230000000694 effects Effects 0.000 description 24
241000700159 Rattus Species 0.000 description 22
241001465754 Metazoa Species 0.000 description 16
239000000203 mixture Substances 0.000 description 14
230000000949 anxiolytic effect Effects 0.000 description 11
230000027455 binding Effects 0.000 description 11
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 10
238000000034 method Methods 0.000 description 9
206010010904 Convulsion Diseases 0.000 description 8
102000014914 Carrier Proteins Human genes 0.000 description 7
108091008324 binding proteins Proteins 0.000 description 7
210000004556 brain Anatomy 0.000 description 7
239000011575 calcium Substances 0.000 description 7
241001515942 marmosets Species 0.000 description 7
230000004044 response Effects 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
108091006146 Channels Proteins 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
230000001773 anti-convulsant effect Effects 0.000 description 6
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 5
PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
238000000692 Student's t-test Methods 0.000 description 5
239000002249 anxiolytic agent Substances 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
229960004782 chlordiazepoxide Drugs 0.000 description 5
ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 5
229940079593 drug Drugs 0.000 description 5
229960003692 gamma aminobutyric acid Drugs 0.000 description 5
229960005425 nitrendipine Drugs 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000001961 anticonvulsive agent Substances 0.000 description 4
229960003965 antiepileptics Drugs 0.000 description 4
238000003556 assay Methods 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000009467 reduction Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000012353 t test Methods 0.000 description 4
108090000312 Calcium Channels Proteins 0.000 description 3
102000003922 Calcium Channels Human genes 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 3
229930195711 D-Serine Natural products 0.000 description 3
206010021143 Hypoxia Diseases 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
208000006011 Stroke Diseases 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
229940024606 amino acid Drugs 0.000 description 3
238000000540 analysis of variance Methods 0.000 description 3
230000000049 anti-anxiety effect Effects 0.000 description 3
JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 3
230000002490 cerebral effect Effects 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000009826 distribution Methods 0.000 description 3
206010015037 epilepsy Diseases 0.000 description 3
235000013305 food Nutrition 0.000 description 3
235000011187 glycerol Nutrition 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
210000002027 skeletal muscle Anatomy 0.000 description 3
239000000243 solution Substances 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 2
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
206010002869 Anxiety symptoms Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
206010061334 Partial seizures Diseases 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000003556 anti-epileptic effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
229940049706 benzodiazepine Drugs 0.000 description 2
208000029028 brain injury Diseases 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
230000007954 hypoxia Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000003446 ligand Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000002287 radioligand Substances 0.000 description 2
238000012552 review Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
230000002792 vascular Effects 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
MXNASYICBPHSLF-UHFFFAOYSA-N 2-[1-(aminomethyl)cycloheptyl]acetic acid Chemical compound OC(=O)CC1(CN)CCCCCC1 MXNASYICBPHSLF-UHFFFAOYSA-N 0.000 description 1
MKGSCDBHUPQQMX-UHFFFAOYSA-N 2-[1-(aminomethyl)cyclopentyl]acetic acid Chemical compound OC(=O)CC1(CN)CCCC1 MKGSCDBHUPQQMX-UHFFFAOYSA-N 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
206010002660 Anoxia Diseases 0.000 description 1
241000976983 Anoxia Species 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
241000288950 Callithrix jacchus Species 0.000 description 1
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
206010014498 Embolic stroke Diseases 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
208000006083 Hypokinesia Diseases 0.000 description 1
206010021118 Hypotonia Diseases 0.000 description 1
102000004016 L-Type Calcium Channels Human genes 0.000 description 1
108090000420 L-Type Calcium Channels Proteins 0.000 description 1
125000003338 L-glutaminyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
208000007379 Muscle Hypotonia Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
241000282887 Suidae Species 0.000 description 1
240000006474 Theobroma bicolor Species 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
102000015007 alpha-adrenergic receptor activity proteins Human genes 0.000 description 1
108040006816 alpha-adrenergic receptor activity proteins Proteins 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000007953 anoxia Effects 0.000 description 1
230000000573 anti-seizure effect Effects 0.000 description 1
230000002921 anti-spasmodic effect Effects 0.000 description 1
230000001353 anxiety effect Effects 0.000 description 1
230000000338 anxiogenic effect Effects 0.000 description 1
229940005530 anxiolytics Drugs 0.000 description 1
206010003549 asthenia Diseases 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
230000003925 brain function Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
229960002495 buspirone Drugs 0.000 description 1
HJQOMCVHLXVRAK-UHFFFAOYSA-N butyl 2-[1-(aminomethyl)cycloheptyl]acetate Chemical compound CCCCOC(=O)CC1(CN)CCCCCC1 HJQOMCVHLXVRAK-UHFFFAOYSA-N 0.000 description 1
IPNWNGVBVWEYLT-UHFFFAOYSA-N butyl 2-[1-(aminomethyl)cyclohexyl]acetate Chemical compound CCCCOC(=O)CC1(CN)CCCCC1 IPNWNGVBVWEYLT-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
238000013172 carotid endarterectomy Methods 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
238000002585 cerebral angiography Methods 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000011363 dried mixture Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000428 dust Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
PQCNPWAMVMHDID-UHFFFAOYSA-N ethyl 2-[1-(aminomethyl)cyclohexyl]acetate Chemical compound CCOC(=O)CC1(CN)CCCCC1 PQCNPWAMVMHDID-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 1
230000003483 hypokinetic effect Effects 0.000 description 1
238000005286 illumination Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000004807 localization Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
210000005171 mammalian brain Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
BPUUTTKHBSNDRT-UHFFFAOYSA-N methyl 2-[1-(aminomethyl)cycloheptyl]acetate Chemical compound COC(=O)CC1(CN)CCCCCC1 BPUUTTKHBSNDRT-UHFFFAOYSA-N 0.000 description 1
SYKKFHNKTXXXCK-UHFFFAOYSA-N methyl 2-[1-(aminomethyl)cyclohexyl]acetate Chemical compound COC(=O)CC1(CN)CCCCC1 SYKKFHNKTXXXCK-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
229960005152 pentetrazol Drugs 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical class CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
210000004129 prosencephalon Anatomy 0.000 description 1
238000000734 protein sequencing Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
210000001747 pupil Anatomy 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000008213 purified water Substances 0.000 description 1
238000003653 radioligand binding assay Methods 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000005096 rolling process Methods 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000035939 shock Effects 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
208000020431 spinal cord injury Diseases 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000012956 testing procedure Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000012549 training Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
229910052721 tungsten Inorganic materials 0.000 description 1
239000010937 tungsten Substances 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
230000006441 vascular event Effects 0.000 description 1
238000007631 vascular surgery Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
208000016258 weakness Diseases 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Anesthesiology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Indole Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)

SK90-97A 1994-07-27 1995-07-11 Liečivo na liečenie úzkosti a panického strachu SK283711B6 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US28128594A	1994-07-27	1994-07-27
US08/445,398 US5792796A (en)	1994-07-27	1995-06-06	Methods for treating anxiety and panic
PCT/US1995/008702 WO1996003122A2 (en)	1994-07-27	1995-07-11	Use of gabapentin in the treatment of anxiety and panic

Publications (2)

Publication Number	Publication Date
SK9097A3 SK9097A3 (en)	1998-05-06
SK283711B6 true SK283711B6 (sk)	2003-12-02

Family

ID=26960801

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK90-97A SK283711B6 (sk)	1994-07-27	1995-07-11	Liečivo na liečenie úzkosti a panického strachu

Country Status (18)

Country	Link
EP (1)	EP0804182B1 (de)
JP (1)	JPH10503490A (de)
AT (1)	ATE218334T1 (de)
AU (1)	AU703428B2 (de)
CA (1)	CA2193384C (de)
CZ (1)	CZ291757B6 (de)
DE (1)	DE69526972T2 (de)
DK (1)	DK0804182T3 (de)
ES (1)	ES2176334T3 (de)
HU (4)	HU0102043D0 (de)
MX (1)	MX9606674A (de)
NZ (1)	NZ290050A (de)
PL (1)	PL187064B1 (de)
PT (1)	PT804182E (de)
RO (1)	RO120041B1 (de)
RU (1)	RU2168982C2 (de)
SK (1)	SK283711B6 (de)
WO (1)	WO1996003122A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5712158A (en) *	1995-06-06	1998-01-27	Warner-Lambert Company	Cell line for the rapid expression of functional calcium channels
US6372792B1 (en)	1996-04-26	2002-04-16	Guy Chouinard	Method for treating anxiety, anxiety disorders and insomnia
IL126999A (en)	1996-07-24	2002-03-10	Warner Lambert Co	Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
ATE323067T1 (de)	1997-10-27	2006-04-15	Warner Lambert Co	Zyklische aminosäuren und deren derivate als arzneimittel
WO1999061424A1 (en) *	1998-05-26	1999-12-02	Warner-Lambert Company	Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
FR2781793B1 (fr)	1998-08-03	2001-07-20	Prographarm Lab	Procede de fabrication de granules de gabapentine enrobes
JP2003512602A (ja) *	1999-09-16	2003-04-02	ワーナー−ランバート・カンパニー	α２δ−１サブユニット結合リガンドのスクリーニング方法
RU2286151C2 (ru) *	2002-02-22	2006-10-27	Уорнер-Ламберт Компани Ллс	Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2
RU2377234C2 (ru) *	2003-09-17	2009-12-27	Ксенопорт, Инк.	Лечение или предупреждение синдрома беспокойных ног с использованием пролекарств аналогов гамк

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2016465A1 (en) *	1989-06-02	1990-12-02	Zola Phillip Horovitz	Method for preventing or treating anxiety employing a calcium channel blocker
US5189026A (en) *	1991-06-07	1993-02-23	Fractal Laboratories, Inc.	Treatment of human diseases involving dysregulation or dysfunction of the nervous system
JP3856816B2 (ja) *	1992-05-20	2006-12-13	ノースウェスターンユニヴァーシティ	抗発作治療用のｇａｂａ及びｌ−グルタミン酸類縁体

1995
- 1995-07-11 RU RU97101109/14A patent/RU2168982C2/ru not_active IP Right Cessation
- 1995-07-11 CZ CZ1997162A patent/CZ291757B6/cs not_active IP Right Cessation
- 1995-07-11 WO PCT/US1995/008702 patent/WO1996003122A2/en not_active Ceased
- 1995-07-11 HU HU0102043A patent/HU0102043D0/hu unknown
- 1995-07-11 JP JP8505766A patent/JPH10503490A/ja not_active Ceased
- 1995-07-11 AU AU30069/95A patent/AU703428B2/en not_active Ceased
- 1995-07-11 HU HU9700238A patent/HU223841B1/hu not_active IP Right Cessation
- 1995-07-11 ES ES95926249T patent/ES2176334T3/es not_active Expired - Lifetime
- 1995-07-11 SK SK90-97A patent/SK283711B6/sk unknown
- 1995-07-11 DE DE69526972T patent/DE69526972T2/de not_active Expired - Fee Related
- 1995-07-11 DK DK95926249T patent/DK0804182T3/da active
- 1995-07-11 HU HU0102040A patent/HU0102040D0/hu unknown
- 1995-07-11 RO RO97-00128A patent/RO120041B1/ro unknown
- 1995-07-11 HU HU0102041A patent/HU0102041D0/hu unknown
- 1995-07-11 EP EP95926249A patent/EP0804182B1/de not_active Expired - Lifetime
- 1995-07-11 PL PL95318268A patent/PL187064B1/pl not_active IP Right Cessation
- 1995-07-11 NZ NZ290050A patent/NZ290050A/xx unknown
- 1995-07-11 PT PT95926249T patent/PT804182E/pt unknown
- 1995-07-11 MX MX9606674A patent/MX9606674A/es active IP Right Grant
- 1995-07-11 CA CA002193384A patent/CA2193384C/en not_active Expired - Fee Related
- 1995-07-11 AT AT95926249T patent/ATE218334T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP0804182B1 (de)	2002-06-05
CZ291757B6 (cs)	2003-05-14
CA2193384A1 (en)	1996-02-08
PL318268A1 (en)	1997-05-26
PL187064B1 (pl)	2004-05-31
ATE218334T1 (de)	2002-06-15
DK0804182T3 (da)	2002-09-09
JPH10503490A (ja)	1998-03-31
EP0804182A2 (de)	1997-11-05
AU3006995A (en)	1996-02-22
MX9606674A (es)	1997-03-29
HU0102043D0 (en)	2001-07-30
CZ16297A3 (en)	1997-07-16
DE69526972D1 (de)	2002-07-11
AU703428B2 (en)	1999-03-25
DE69526972T2 (de)	2002-11-21
HU223841B1 (hu)	2005-02-28
RO120041B1 (ro)	2005-08-30
WO1996003122A2 (en)	1996-02-08
CA2193384C (en)	2002-03-19
HUT76835A (en)	1997-11-28
ES2176334T3 (es)	2002-12-01
HU0102041D0 (en)	2001-07-30
PT804182E (pt)	2002-10-31
WO1996003122A3 (en)	1996-07-18
NZ290050A (en)	1999-08-30
HU0102040D0 (en)	2001-07-30
RU2168982C2 (ru)	2001-06-20
SK9097A3 (en)	1998-05-06

Publication	Publication Date	Title
Vas et al.	2005	Eburnamine derivatives and the brain
DE69930552T2 (de)	2006-11-30	Exo-s-mecamylamin-formulierung und ihre verwendung in behandlungen
WO2002074293A2 (en)	2002-09-26	Methods for restoring cognitive function following systemic stress
Palmer et al.	1992	Biological profile of the metabolites and potential metabolites of the anticonvulsant remacemide
HUE033180T2 (en)	2017-11-28	Peptide compounds for the treatment of difficult to cure epileptic diseases
US5792796A (en)	1998-08-11	Methods for treating anxiety and panic
SK283711B6 (sk)	2003-12-02	Liečivo na liečenie úzkosti a panického strachu
CN1044367C (zh)	1999-07-28	(S)－α－苯基－2－吡啶乙胺,其制法及含该化合物的组合物
Marquis et al.	1987	Animal models of intravenous phencyclinoid self-administration
KR102269493B1 (ko)	2021-06-25	(r)-디미라세탐 (1) 및 (s)-디미라세탐 (2)을 비-라세미 비로 포함하는 상승작용적 조성물
Kocsis et al.	1996	GABA levels in the brain: a target for new antiepileptic drugs
Löscher et al.	1993	Effects of the competitive NMDA receptor antagonist, CGP 37849, on anticonvulsant activity and adverse effects of valproate in amygdala-kindled rats
Heinemann et al.	1991	4. In vitro epileptiform activity: role of excitatory amino acids
JP3363440B2 (ja)	2003-01-08	脊髄小脳変性症治療剤および脊髄小脳変性症治療用組成物
JPH03209355A (ja)	1991-09-12	アリールアルキルアミド含有の神経変性疾患治療剤
Windisch et al.	1996	COGNITION-ENHANCING
AU735816B2 (en)	2001-07-19	Use of gabapentin in the treatment of anxiety and panic
Nidhin et al.	2021	Experimental study on antiepileptic action of Kousheyashma Bhasma
AU2005247114B2 (en)	2010-06-03	Use of neboglamine (CR 2249) as an antipsychotic and neuroprotective
Sapronov et al.	1997	P. 6.046 Pharmacology of some new DL-aspartic acid derivatives
NZ336674A (en)	2000-10-27	Use of gabapentin in the treatment of anxiety and panic
Allen	1996	A review of the actions of d-cycloserine, a putative nootropic agent, at the NMDA receptor complex-associated glycine binding site
KR20210099566A (ko)	2021-08-12	R-2-(치환된-술포닐)-헥사히드로-피롤로[1,2-a]피라진-6(2H)-온 및 S-2-(치환된-술포닐)-헥사히드로-피롤로[1,2-a]피라진-6(2H)-온을 비-라세미 비로 포함하는 상승작용적 조성물
Poschel	2013	NEW PHARMACOLOGICAL PERSPECTIVES ON NOOTROPIC
Kulikova et al.	1997	P. 6.047 Regulatory system of brain chromatin in nootropic action